1. Home
  2. ALX vs CRVS Comparison

ALX vs CRVS Comparison

Compare ALX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

N/A

Current Price

$243.83

Market Cap

1.3B

Sector

Real Estate

ML Signal

N/A

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

N/A

Current Price

$10.93

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALX
CRVS
Founded
1928
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
ALX
CRVS
Price
$243.83
$10.93
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $33.14
AVG Volume (30 Days)
21.3K
★ 897.5K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
★ 7.30%
N/A
EPS Growth
N/A
★ 48.04
EPS
★ 31.15
N/A
Revenue
★ $213,183,000.00
N/A
Revenue This Year
$14.78
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.93
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$201.28
$6.39
52 Week High
$289.43
$26.95

Technical Indicators

Market Signals
Indicator
ALX
CRVS
Relative Strength Index (RSI) 30.44 36.67
Support Level $234.50 $11.13
Resistance Level $251.04 $13.73
Average True Range (ATR) 4.38 0.69
MACD 0.02 -0.09
Stochastic Oscillator 0.00 19.00

Price Performance

Historical Comparison
ALX
CRVS

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: